10.1016/S0140-6736(21)01324-6 [DOI] [PubMed] 184.Dahl D, Onishi Y, Norwood P, et al
In November 2025, Novo Nordisk and Eli Lilly both reached similar deals with the Trump administration to sell the lowest dose of oral GLP-1 medications for $149 per month out of pocket
Ozempic binds to receptors in the brain, pancreas, and digestive system, helping to improve blood glucose control and reduce hunger
Head-to-head Study Shows Bariatric Surgery Superior
References: Baggio LL, Drucker DJ (2007): Biology of incretins: GLP-1 and GIP
A study published in JAMA in January 2025 which looked at more than 125,000 overweight or obese people found that nearly 47% of those with type 2 diabetes and 65% of those without diabetes stopped taking their prescribed GLP-1s within a year of starting them